Gabriela Hobbs/Massachusetts General Hospital
Sep 4, 2025, 18:00
SOHO 2025: Gabriela Hobbs on Emerging Strategies for Managing Polycythemia Vera and Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Gabriela Hobbs, Massachusetts General Hospital News
Discusses novel therapies in development for treatment of Polycythemia Vera, including modulators of hepcidin-ferroportin, bomedemstat, givinostat, and novel JAKis, and in Essential Thrombocythemia, including ropeginterferon, bomedemstat, and CALR-directed agents.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Jun 17, 2026, 17:47Anuoluwapo Oladunjoye: Every Blood Film Has a Story to Tell
-
Jun 17, 2026, 17:46Svetislav Matic: A Patient-Centric Interdisciplinary Approach to Perioperative Bleeding Management
-
Jun 17, 2026, 17:45Paul Breillat: New Insights Into the Role of RIPK1-Mediated Cell Death in VEXAS syndrome
-
Jun 17, 2026, 17:44Konstantin Yenkoyan: New Publication Alert – Autism and Iron Dysregulation
-
Jun 17, 2026, 17:44Ifeanyichukwu Ifechidere: Why Fibrinolysis Matters as Much as Clot Formation
-
Jun 17, 2026, 17:17Soma Agrawal: Transfusion Medicine in India – How Far We Have Come, and How Far We Must Go
-
Jun 17, 2026, 16:52Asayil Basalim: A Milestone in Medical Laboratory Science Training
-
Jun 17, 2026, 16:43Aleksandra Pikula: Canada’s First Women in Midlife Brain Health and Stroke Prevention Program Is Officially Launched
-
Jun 17, 2026, 16:42Alejandro González Veliz: Not Every Acs Patient Needs 12 Months of Dapt